Login to Your Account

Other news to note

Friday, March 18, 2016

Elite Pharmaceuticals Inc., of Northvale, N.J., gained FDA acceptance of its new drug application for Sequestox (ELI-200), the company's lead opioid abuse-deterrent candidate for the management of moderate to severe pain where the use of an opioid analgesic is appropriate. The agency has set a PDUFA date of of July 14 for the drug.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription